Introduction

▼
In Europe, lamotrigine is licensed for 2 indications: in neurology for the treatment of epilepsy and in psychiatry for the prevention or at least delay of depressive episodes in bipolar-I disorders of adults [1] . In clinical trials lamotrigine was not more effective than placebo in the treatment of acute manic or depressive episodes [2] . For anticonvulsant treatment, the accepted TRR of lamotrigine is 3 000-14 000 ng/ml [3] . Although TDM is recommended to optimize treatment of bipolar disorders with lamotrigine (recommendation level 2 [3] ), thus far there is no particular TRR for that indication. Therefore, this study was designed to check if another TRR has to be established for TDM-guided treatment of bipolar disorder.
Materials and Methods
▼
KONBEST, a database continuously filled with TDM data under conditions of daily routine, was analyzed [4] . Besides the clinical reasons for (3), much (2) or very much improved (1) were considered as responders.
Results:
The recommended lamotrigine maintenance dose for bipolar disorder is 200 mg/day; the doses prescribed in our samples ranged from 25 to 450 mg/day. Only 32 concentrations (39.0 %) fitted into the TRR recommended for therapy of epilepsy; 50 (61.0 %) did not reach it, none exceeded it. The lowest concentration was 177 ng/ml, the highest 11 871 ng/ml. A mean lamotrigine serum concentration of 3 341 ± 2 563 ng/ml (̅ x ± SD) was detected in the patients who benefitted. Discussion: The authors conclude that in bipolar disorder lower lamotrigine serum concentrations lead to therapeutic benefit.
Lamotrigine serum concentrations were plotted against the resulting CGI-I scores and against the prescribed doses. Unless otherwise indicated, population data are given as ̅ x ± 1SD. The correlation was statistically validated by linear regression and Pearson correlation. p < 0.05 was set as statistically significant.
Results
▼
3 459 data sets were identified in the KONBEST database with blood specimens quantified for lamotrigine. A diagnosis was submitted with 1 471 of the specimens; 360 patients suffered from bipolar disorder (F31, [7] ). 82 of them benefitted from therapy with lamotrigine ( = 100 % of responders 57 patients with a CGI-I score of 3 (minimally improved) had a mean serum concentration of 3 118 ± 2 522 ng/ml with a mean dose of 154.4 ± 82.7 mg/day. 21 patients with a CGI-I score of 2 had mean serum concentrations of 4 092 ± 2 608 ng/ml with a mean dose of 173.8 ± 75.0 mg/day. Only 4 samples were available from patients with a CGI-I score of 1. Their mean serum concentration was 2 578 ± 2 033 ng/ml, the mean prescribed dose was 200.0 ± 100.0 mg/day ( • ▶ Fig. 3 ). No positive linear correlation could be statistically validated between lamotrigine serum concentrations and CGI-I scores (p = -0.080). Correlating just the lamotrigine concentrations to CGI-I scores 2 and 3, a higher serum concentration of lamotrigine seems to lead to therapeutically better effects. But this difference could not be statistically validated. The arithmetic mean of lamotrigine serum concentrations of all 82 responders was calculated as 3 341 ± 2 563 ng/ml. Non-responders (CGI-I score 4-7) had mean lamotrigine serum levels of 3 483.23 ± 2 556.58 ng/ml ( • ▶ Fig. 4 ).
Discussion
▼
There is no doubt that it is the concentration of a drug, not its dose, that is responsible for its efficacy. Therefore quantifying the concentration of a drug in an individual patient should always be the basis of drug therapy ( = therapeutic drug monitoring, TDM). High-quality equipment and analytical methods, valid reference ranges (DRR [8] and TRR) as well as a clinical pharmacological comment interpreting the measured value [9] are needed to optimize pharmacotherapy with TDM [3, 10] . KONBEST is a web-based laboratory information system especially designed to allow handling and commenting of TDM data; it is connected to a database that stores all necessary data on a strictly anonymous basis [4, 10] . Unfortunately there are no clinical studies yet particularly designed to validate a TRR for the use of lamotrigine in bipolar disorder. The only TRR available for TDM is the one established for the prevention of epileptic seizures. Unless otherwise proven the same concentrations do not have to be necessarily effective for the prevention of depressive episodes in bipolar disorders, too. In quantifying lamotrigine in patients' samples within the daily routine, it has been our impression that many concentrations were below the neurologic TRR. In psychiatry, lower serum concentrations than in antiepileptic therapy seemed to have a therapeutic effect. We found 3 publications in the literature that addressed the topic as well. Katayama et al. determined lamotrigine concentrations under the lamotrigine doses recom- mended for bipolar disorder in 25 Asian patients suffering from various kinds of mood disorders (18 BP-II patients, 1 BP-I patient, 5 major depressive patients) and suggested a therapeutic reference range of 5 000-11 000 ng/ml [11] . Lamotrigine clearance is 28.7 % lower in the Asian population [12] . This may explain why Katayama et al. detected such high serum concentrations under the dosage that is uniquely recommended for bipolar disorders all over the world. The same holds true for the study by Kagawa et al., who studied 34 patients suffering from various kinds of treatment-resistant affective disorders; 12 patients were not treated for a bipolar disorder but for a unipolar depressive episode [13] . Kagawa et al. even suggested a lamotrigine concentration above 12 700 nmol/L, which in our opinion was necessary because the symptomatology of their patients had already proven to be treatment-resistant. This study population is not the population lamotrigine is licensed for in psychiatry. A European study by Grunze et al. had earlier suggested that lower lamotrigine concentrations were effective in bipolar disorders [14] . These authors had observed 14 rapid cycling patients who were treated either with lamotrigine or lithium in monotherapy for one year. 3 patients did not have any mood episode under lamotrigine therapy. All of them had serum levels above 5 000 ng/ml, while partial or non-responders had serum levels between 2 400 and 4 900 ng/ml. This prompted us to retrospectively analyze the data in our KON-BEST database, in which all data obtained during our daily routine of quantifying drug serum concentrations were stored anonymously since 2006 [4] . An advantage of this approach is the large amount of data (3 459 samples) we could include in this analysis compared to the earlier publications. It is a pity, however, the indication was given in only 43 % of the lamotrigine requests, demonstrating how little attention is paid under routine conditions to properly filling in request forms. Nevertheless, 82 data sets remained for our analysis, still 2-4 times the number of cases reported in the earlier publications. Moreover, we could restrict the diagnosis to ICD-10 F31 (bipolar affective disorder), whereas Grunze et al. studied only rapid cycling patients, Katayama et al. patients suffering from all kinds of affective disorders (among them many unipolar depressed patients), and Kagawa et al. treatment-resistant affective disorders. The lamotrigine maintenance dose recommended for bipolar disorder is 200 mg/day; in our samples lamotrigine was actually prescribed very carefully, with > 50 % of the patients prescribed less than the recommended dosage. Therefore it is not surprising that most of the serum concentrations detected were below the TRR. The data presented here demonstrate that just roughly half of the patients were within the expected DRR. The other concentrations deviated from the expected DRR. Most of the concentrations that did not reach the DRR were diagnosed in the clinical pharmacological comment as compliance problems; most of the concentrations that exceeded the DRR exceeded it because of drug-drug interactions, which means that some of the patients may have reached the neurologic TRR only because of a drugdrug interaction inhibiting the metabolizing enzyme. Remarkable in this regard are the patients under comedication with valproate. This drug-drug interaction is well known. Lamotrigine is mainly metabolized by conjugation with glucuronic acid and not by the cytochrome-P 450 -isoenzyme (CYP) system in the liver. The major metabolite is an inactive 2-N-glucuronide conjugate [15] . Valproate blocks the glucuronisation of lamotrigine thereby increasing lamotrigine blood concentration. It is generally recommended to avoid this drug-drug interaction (contraindication). In our opinion, the dosage of lamotrigine must instead be properly adapted, i. e., TDM-guided. As little as 25 mg/day may suffice to reach the TRR as has been shown earlier in a case report [16] . Kagawa et al. lowered their lamotrigine dosage in combination with valproate just by 25 % [13] . In our study the arithmetic mean of lamotrigine serum concentrations of all 82 responders was calculated as 3 341 ± 2 563 ng/ml. This implies that lower lamotrigine serum concentrations may suffice for the treatment of bipolar disorder than currently recommended [3] . Non-responders (CGI-I scores 4-7) had mean lamotrigine serum levels of 3 483.23 ± 2 556.58 ng/ml. The difference between the groups was not statistically significant. But our data show clinical reality: some of the non-responders might have benefitted from therapy with lamotrigine if the dose had been properly elevated. On the other hand, there are also non-responders with quite high lamotrigine levels. We believe that their disease simply did not respond to lamotrigine; these patients belong to the population studied by Kagawa et al. [13] . We decided not to split our responders with different CGI-I scores into separate groups because we did not find significant differences between them. The low number of 4 patients with the CGI-I score 1 is due to our patient selection in a retrospective study. Physicians today still decide to draw blood from a patient for quantification of a drug concentration if the therapy does not proceed as expected; usually no blood is drawn from a patient that improves. This, however, is the most important group of patients if a valid TRR is to be established to prevent depressive episodes in bipolar disorder. This is a retrospective study. Retrospective studies always have more or less significant drawbacks. Compared to the small older studies, it is an advantage that we were able to clearly restrict the diagnosis of our patients to just bipolar patients (F31). The clinical improvement of our patients was judged by CGI-I scores, which is a very general and subjective measure of a patient's clinical state; therefore we do not know which symptom in each patient actually improved. In a prospective study the prevention of depressive episodes should be the primary study endpoint. Nevertheless, our data support the hypothesis that much lower lamotrigine concentrations suffice to treat patients suffering from bipolar disorder and responding to lamotrigine than the TRR currently accepted in neurology suggests. We support the proposal of Grunze et al. and of Katayama et al. We agree that the lamotrigine concentration of 14 000 ng/ml suggested to treat epilepsy does not have to be reached in bipolar disorder. We hardly found such high serum concentrations in our samples.
There is no doubt that the results and consideration of this study have to be confirmed in a well-designed prospective clinical trial. Our study is just a pilot study to prepare for such a study. Based on our findings such a study should ▶ strictly focus on the licensed indication, i. e., the prevention of depressive episodes in bipolar disorder; ▶ exclude patients with treatment-resistant bipolar disorders, ▶ evaluate the effectiveness of lamotrigine by a validated instrument such as the Montgomery-Åsberg Depression Rating Scale (MADRS), and ▶ increase the lamotrigine dosage slowly and with TDM guidance into the range of 3 300 ± 2 500 ng/ml. Keeping in mind that lamotrigine is no longer a patented substance, we are not very confident that such a study will be conducted in the near future. Such studies are actually best included in the license study program. Unfortunately, determination of drug concentrations is not yet obligatory. We ask the drug authorities to include quantification of the drug concentration into the license studies to obtain information on individual effects instead of correlating just the dose to its clinical efficacy in a population-based approach.
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